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Type 2 diabetes is a chronic illness that is increasing in epidemic proportions worldwide.
Major factors contributing to the development of type 2 diabetes include obesity and
poor lifestyle habits (e.g., excess dietary intake and limited physical activity). Despite the
proven efficacy of lifestyle interventions and the use of multiple pharmacological agents,
the economic and public health burden of type 2 diabetes remains substantial. Obstruc-
tive sleep apnea (OSA) is a treatable sleep disorder that is pervasive among overweight
and obese adults, who represent about two thirds of the U.S. population today. An ever-
growing number of studies have shown that OSA is associated with insulin resistance,
glucose intolerance and type 2 diabetes, independent of obesity. Evidence from animal
and human models that mimic OSA provides potential mechanisms for how OSA may
alter glucose metabolism. Up to 83% of patients with type 2 diabetes suffer from unrec-
ognized OSA and increasing severity of OSA is associated with worsening glucose control.
However, it is still unclear whether OSA may lead to the development of diabetes over time.
More data from large-scale longitudinal studies with rigorous assessments of diabetes and
OSA are needed. In addition, there is still controversy whether continuous positive airway
pressure (CPAP) treatment of OSA improves glucose metabolism. Large-scale randomized-
controlled trials of CPAP treatment of OSA with well-validated assessments of insulin
sensitivity and glucose tolerance are needed. These studies may reveal that OSA rep-
resents a novel, modifiable risk factor for the development of prediabetes and type 2
diabetes.
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Obstructive sleep apnea (OSA) is a treatable sleep disorder that
is pervasive among overweight and obese adults, who represent
about two-thirds of the U.S. population today. Prevalence esti-
mates of OSA in obese adults (aged 30–69 years) range from 11 to
46% in women and 33 to 77% in men (Young et al., 2005). More-
over, weight gain longitudinally predicts increased OSA incidence
and severity (Peppard et al., 2000; Newman et al., 2005).
Over the past decade, there has been a rising interest in the
cardiometabolic derangements associated with OSA (reviewed in
Punjabi and Polotsky, 2005; Somers et al., 2008; Tasali and Ip,
2008; Tasali et al., 2008b; Jun and Polotsky, 2009; Levy et al., 2009).
Current data suggests that OSA may play a role in adverse cardio-
vascular outcomes (Yaggi et al., 2005; Young et al., 2008; Redline
et al., 2010). A large number of studies have shown that OSA is
associated with insulin resistance, glucose intolerance, and type
2 diabetes, independent of obesity. In this article, we will review
the current evidence from studies that address frequently asked
questions regarding the links between OSA, type 2 diabetes, and
prediabetic states.
WHAT IS THE NATURAL HISTORY OF TYPE 2 DIABETES?
Type 2 diabetes is a chronic illness that is increasing in epidemic
proportions worldwide. It affects 25.6 million adults in the U.S.,
with an estimated 1.9 million new diagnoses per year [Center
for Disease Control (CDC), 2011]. Major factors contributing
to the development of type 2 diabetes include obesity and poor
lifestyle habits (e.g., excess dietary intake and limited physical
activity). The current standard criteria for the diagnosis of type
2 diabetes are as follows: (1) Hemoglobin A1c (A1c) ≥6.5%, or
(2) fasting plasma glucose ≥126 mg/dl, or (3) 2 h plasma glu-
cose ≥200 mg/dl during an oral glucose tolerance test (OGTT),
or (4) random plasma glucose ≥200 mg/dl in a patient with clas-
sic symptoms of hyperglycemia [American Diabetes Association
(ADA), 2010].
High glucose levels not sufficient to meet the diagnostic crite-
ria for type 2 diabetes are considered as prediabetic states, namely
impaired fasting glucose (IFG) and impaired glucose tolerance
[IGT; American Diabetes Association (ADA), 2010]. According
to the CDC, 35% of U.S. adults aged 20 years or older may have
prediabetes, which suggests that prediabetic states exist in an esti-
mated 79 million Americans [Center for Disease Control (CDC),
2011]. Fasting plasma glucose levels that are in the range of 100–
125 mg/dl define an IFG state. A 2-h plasma glucose level during
the 75-g OGTT that is in the range of 140–199 mg/dl defines an
IGT state. In prediabetic states, the A1c ranges between 5.7 and
6.4% [American Diabetes Association (ADA), 2010]. The hallmark
of prediabetic states is insulin resistance. Transition from the early
states of impaired glucose metabolism to frank diabetes may take
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Table 1 | Various methods used in the assessment of glucose metabolism*.
Method Description Reliability and interpretation
Fasting plasma glucose
(FPG) and insulin
Plasma glucose and serum insulin levels are measured in
a fasting blood sample
Impaired fasting glucose (IFG) is diagnosed if FPG is between
100 and 125 mg/dl
Diabetes is diagnosed if fasting glucose levels are ≥126 mg/dl
[American Diabetes Association (ADA), 2010]
Hemoglobin A1c (A1c) Measured in a single blood sample and reflects glucose
control over the preceding 2–3 months
Diabetes if hemoglobin A1c ≥6.5% Prediabetes if hemoglobin
A1c is between 5.7 and 6.4% [American Diabetes Association
(ADA), 2010]
Monitoring of hemoglobin A1c is used in clinical practice for
diabetes management and is the primary target for glycemic
control
Lowering hemoglobin A1c below 7% has been associated with
a reduction of diabetic complications [American Diabetes
Association (ADA), 2010]
Homeostatic model
assessment (HOMA)
index
The normalized product of fasting glucose and insulin
calculated using the following formula: (fasting serum
insulin× fasting plasma glucose)/22.5
Reliable and validated estimate of insulin resistance (Matthews
et al., 1985)
Elevated HOMA levels reflect higher degrees of insulin
resistance
Oral glucose tolerance
test (OGTT)
After ingestion of 75 g of glucose, blood samples are
collected for the measurement of glucose and insulin
concentrations at time 30, 60, 90, and 120 min to
evaluate glucose tolerance
A clinical tool used for the diagnosis of type 2 diabetes
[American Diabetes Association (ADA), 2010]
Normal glucose tolerance (NGT), impaired glucose tolerance
(IGT), or diabetes is diagnosed if the glucose level at 2 h is less
than 140 mg/dl, between 140–199 mg/dl, or 200 mg/dl or more,
respectively
Continuous glucose
monitoring system
Glucose concentration in the interstitial fluid is measured
using a subcutaneous sensor attached to a continuous
monitoring device that record sensor signals every 5 min,
providing 288 glucose level readings per day
Used in clinical practice for diabetes management to assess
24 h glucose fluctuations (particularly post-prandial and
nocturnal levels)
Hyperinsulinemic
euglycemic clamp
Insulin sensitivity is quantified by intravenous glucose
infusion rate (i.e., glucose uptake by all the tissues in the
body) under steady state conditions of euglycemia
The gold standard technique used for measurement of insulin
sensitivity (DeFronzo et al., 1979)
Intravenous glucose
tolerance test
Glucose and insulin concentrations are measured during
fasting and after intravenous glucose injection at frequent
intervals for 4 h
Validated tool that allows to simultaneously assess glucose
tolerance, beta-cell responsiveness, and insulin sensitivity
using a mathematical model (Bergman, 2005)
*Reprinted with permission of the American Thoracic Society. Copyright © 2008 American Thoracic Society.
Tasali and Ip (2008), An official Journal of The American Thoracic Society.
several years, and it is estimated that∼70% prediabetic individuals
eventually develop type 2 diabetes (Nathan et al., 2007). The most
commonly used clinical and research methods to assess glucose
tolerance, insulin sensitivity, and secretion are summarized in
Table 1.
In normal individuals, insulin resistance is compensated by an
up-regulation of insulin secretion to maintain normal glucose tol-
erance. According to the “hyperbolic law of glucose tolerance,”
under normal conditions the product of insulin sensitivity and
secretion (i.e., the disposition index; DI) is constant (Bergman,
2005). In individuals who are at risk for developing type 2 diabetes,
the DI may be reduced due to inadequate compensatory insulin
secretion for a given degree of insulin resistance. Thus, type 2
diabetes is a two-step process characterized by both insulin resis-
tance and impaired insulin secretion. Initially, insulin resistance
occurs resulting in progression from a normal glucose tolerant
state to IGT. At this stage, insulin levels are elevated (compensatory
hyperinsulinemia) and beta-cell dysfunction is already present.
Subsequently, progressive decline in beta-cell function occurs,
which leads to development of type 2 diabetes (DeFronzo and
Abdul-Ghani, 2011).
Despite the proven efficacy of lifestyle interventions and the
use of multiple pharmacological agents, the economic and public
health burden of type 2 diabetes remains substantial. Cardiovascu-
lar disease is a major cause of mortality and morbidity in both type
2 diabetes and prediabetes. In addition to cardiovascular disease,
type 2 diabetes is associated with longterm complications affect-
ing the eyes, kidneys, and nervous system. (Kashyap and Defronzo,
2007; Nathan et al., 2007; Mazzone et al., 2008). It is well docu-
mented that both lifestyle modification and metformin use are
effective in reducing the incidence of diabetes (Tuomilehto et al.,
2001; Knowler et al., 2002, 2009). However, even with substan-
tial efforts to achieve lifestyle modification, data suggest that the
effectiveness of this intervention diminishes over time. Thus, the
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development of additional strategies to prevent or delay the onset
of diabetes and its cardiovascular complications remains a critical
public heath challenge.
WHAT IS THE PREVALENCE OF OSA IN TYPE 2 DIABETICS?
The overall prevalence of OSA diagnosed by full polysomnogra-
phy in type 2 diabetic patients is approximately 71% based on
the average of data from five studies including a total number of
nearly 1200 type 2 diabetic patients (Resnick et al., 2003; Einhorn
et al., 2007; Foster et al., 2009; Laaban et al., 2009; Aronsohn et al.,
2010; Table 2). The highest estimate of 86% was reported in obese
diabetic patients enrolled in the multi-center Sleep AHEAD study
(Foster et al., 2009). The lowest estimate of 58% was found in
the Sleep Heart Health Study (Resnick et al., 2003), which is a
multi-center cohort that included older individuals (with more
than half aged over 65 years) and used self-reported diabetes and
a desaturation criteria of 4% for the definition of hypopneas. In
another study by Aronsohn et al., OSA prevalence was found to be
77% using a less stringent cut-off of 3% for oxygen desaturations.
Of note, when the dataset was re-analyzed using more strict 4%
desaturation criteria, this estimate was reduced to 58% (Aronsohn
et al., 2010). These variable prevalence estimates may be due to dif-
ferences in study populations as well as different scoring criteria
used to capture OSA (Redline et al., 2000). Nevertheless, consid-
ering that the prevalence of OSA by full-night polysomnography
in patients with type 2 diabetes averages 71%, this would then
suggest that approximately 19 million diabetics may have undiag-
nosed and untreated OSA. Indeed, a recent retrospective analysis
of a total of 16,066 diabetic patients with one or more primary care
office visits in 27 primary care ambulatory practices has revealed
that only 18% of the study population (23% of obese patients)
carried an OSA diagnosis (Heffner et al., 2012). These findings
suggest that in the primary care setting, OSA is largely unrecog-
nized in patients with diabetes and thus millions of diabetics may
currently suffer from this co-morbidity. In sum, these staggering
statistics emphasize the need for a better understanding of the
links between OSA and type 2 diabetes (Shaw et al., 2008).
WHAT IS THE PREVALENCE AND INCIDENCE OF TYPE 2
DIABETES IN OSA?
Several population and clinic-based studies have assessed the
prevalence and incidence of type 2 diabetes in OSA (Meslier et al.,
2003; Reichmuth et al., 2005; Seicean et al., 2008; Tamura et al.,
2008; Botros et al., 2009; Mahmood et al., 2009; Marshall et al.,
2009; Ronksley et al., 2009; Celen et al., 2010; Fredheim et al.,
2011). The majority of these studies have used validated diabetes
definitions based on fasting glucose or 2 h post-challenge glucose
levels, while a few studies relied on self-reported diabetes and/or
antidiabetic medication use. Most, but not all studies (Marshall
et al., 2009; Ronksley et al., 2009; Celen et al., 2010), used full
polysomnography to diagnose OSA. The majority of studies used
statistical adjustments for shared risk factors such as age, sex, body
mass index (BMI) and various other parameters (e.g., neck and
waist circumference). Overall, the cross-sectional analyses have
shown a significantly higher prevalence of diabetes in patients
with OSA as compared to those without OSA. The prevalence
estimates range from 15 to 30%, depending on the study popu-
lation, the definition of OSA severity, and the methods used to
diagnose type 2 diabetes (Meslier et al., 2003; Reichmuth et al.,
2005; Mahmood et al., 2009; Ronksley et al., 2009; Fredheim et al.,
2011). A few studies have also reported a significant relationship
between increasing severity of OSA and the prevalence of diabetes
(Reichmuth et al., 2005; Tamura et al., 2008; Ronksley et al., 2009;
Samson et al., 2012). In two studies (Mahmood et al., 2009; Mar-
shall et al., 2009), the higher odds ratio for diabetes in patients with
OSA was no longer significant after controlling for confounders.
In one study (Ronksley et al., 2009), a higher adjusted odds of self-
reported diabetes was found only in the severe OSA group who
had excessive sleepiness. In this regard, more research is needed to
elucidate the role of sleepiness in adverse metabolic outcomes and
Table 2 | Studies examining the prevalence of obstructive sleep apnea (OSA) in patients with type 2 diabetes.
Author/year Sample characteristics OSA diagnosis
criteria
Diabetes definition Prevalence estimates
Resnick et al. (2003) n=470 (216 men) AHI ≥5 Self-reported; Use of
diabetes medications
58% with at least mild OSA (AHI ≥5)
Sleep Heart Health Study, USA 24% with moderate-severe OSA (AHI ≥15)
Einhorn et al. (2007) n=62 (31 men) AHI ≥5 Not reported 71% with at least mild OSA (AHI ≥5)
Diabetes clinics 61% with moderate-severe OSA (AHI ≥15)
Foster et al. (2009) n=305 (122 men) AHI ≥5 Self-reported with
verification
86.6% Overall prevalence
Obese patients with type 2
diabetes enrolled in Sleep
AHEAD trial
33.4% Mild OSA
30.5% Moderate OSA
22.6% Severe OSA
Laaban et al. (2009) n=303 (155 men) AHI ≥5 Documented medical
history of diabetes
63% Overall prevalence
Poorly controlled type 2
diabetics from clinics
34% Mild OSA
19% Moderate OSA
10% Severe OSA
Aronsohn et al. (2010) n=60 (27 men) AHI ≥5 Physician diagnosis 77% Overall prevalence
Primary care and endocrinology
clinics
38% Mild OSA
25% Moderate OSA
13% Severe OSA
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Table 3 | Prospective studies examining the incidence of type 2 diabetes in patients with obstructive sleep apnea (OSA).
Author/year Sample
characteristics
OSA diagnosis
criteria
Diabetes
definition
Follow-up
period
Main findings
Reichmuth
et al. (2005)
1387 (779 men);
Wisconsin Sleep
Cohort, USA
AHI ≥5 Physician diagnosis;
Fasting glucose ≥126 mg/dl
4 years
(n=987)
In unadjusted analysis, higher incidence of
diabetes in moderate to severe OSA.
Unadjusted OR=4.06 (CI=1.86–8.85)
After adjustments for age, sex, body habitus, no
increase in diabetes incidence.
Adjusted OR=1.62 (CI=0.67–3.65)
Marshall
et al. (2009)
399 (294 men);
Busselton Health
Study, Australia
AHI ≥5 (limited
PSG)
Physician diagnosis; Use of
diabetes medications;
Fasting glucose ≥126 mg/dl
4 years After adjustments for age, sex, BMI, waist, mean
blood pressure, HDL cholesterol, higher incidence
of diabetes in moderate to severe OSA.
Adjusted OR=13.45 (CI=1.59–114.11)
Botros et al.
(2009)
544 individuals; VA
Connecticut Sleep
Center, USA
AHI ≥8 (full
PSG)
Physician diagnosis;
Fasting glucose ≥126 mg/dl
2.7 years After adjustments for age, sex, race, BMI, baseline
fasting glucose, weight change, higher incidence of
diabetes with increasing severity of OSA.
Adjusted Hazard Ratio per quartile of OSA
severity=1.43 (CI=1.10–1.86)
Celen et al.
(2010)
168 middle-age
adults, sleep
clinics, Sweden
OD ≥30 (limited
PSG)
Physician diagnosis 16 years Significantly higher incidence of diabetes in
patients with OSA compared to no OSA only in
women but not in men
Lindberg
et al. (2012)
156 men,
population-based
cohort, Sweden
AHI >5 Self-reported; Regular
doctor visits for diabetes;
Fasting glucose ≥126 mg/dl
11 years At the follow-up, 23 men had diabetes
After adjustment for age, baseline BMI, change in
BMI, hypertension, and years with CPAP,
increasing severity of oxygen desaturations is a
predictor of developing diabetes.
Adjusted OR=4.4 (CI=1.1–18.1)
AHI, apnea-hypopnea index; CPAP, continuous positive airway pressure; OD, oxygen desaturations.
to better understand the links between OSA and diabetes in sleepy
versus non-sleepy patients.
A total of five prospective studies have examined the incidence
of type 2 diabetes in patients with OSA (Table 3). In the longi-
tudinal follow-up of about 1000 individuals from the Wisconsin
Sleep Cohort (Reichmuth et al., 2005), OSA was found to be a risk
factor for incident diabetes over a 4-year period, but this associ-
ation was no longer significant after adjusting for age, sex, and
body habitus. The Busselton Health Study (Marshall et al., 2009)
reported a significant independent association between moder-
ate to severe OSA and incident diabetes over a 4-year follow-up
period, but the sample size was small with only a few incident cases
of diabetes. In another study by Botros et al. (2009), an indepen-
dent association between OSA and incident diabetes was found
after adjusting for age, sex, race, BMI, baseline fasting glucose and
weight change over a mean follow-up period of 2.7 years. Interest-
ingly, one clinic-based study of 168 middle-aged patients (Celen
et al., 2010), reported a significantly higher incidence of diabetes in
patients with OSA compared to those without OSA in women, but
not in men, after a follow-up period of 16 years. More recently, in a
population-based cohort of 156 men from Sweden (Lindberg et al.,
2012), the increasing severity of oxygen desaturations in OSA was
found to be a predictor of developing diabetes after adjustments
for various confounders including years of treatment for OSA. In
another prospective study of about 4000 middle-aged individuals,
nocturnal intermittent hypoxia was associated with an increased
risk of developing type 2 diabetes after a 3-year median follow-up
(Muraki et al., 2010).
Thus, the current evidence from cross-sectional analyses sug-
gest that type 2 diabetes is more prevalent among patients with
OSA compared to those without OSA, independent of shared risk
factors. However, it is still unclear whether OSA may lead to the
development of diabetes over time. More data from large-scale lon-
gitudinal studies with rigorous assessments of diabetes and OSA
are needed.
DOES UNTREATED OSA ADVERSELY AFFECT GLYCEMIC
CONTROL IN TYPE 2 DIABETIC PATIENTS?
An earlier study including 279 diabetic patients found no signif-
icant associations between OSA and glycemic control, as assessed
by A1c (Einhorn et al., 2007). In this negative study, only about
22% of the study population was assessed by full polysomnog-
raphy and the duration of sleep recording was reported to be as
low as 4 h. In a more recent study (Aronsohn et al., 2010), 60
patients with physician-diagnosed diabetes underwent full labo-
ratory polysomnography (with a minimum laboratory recording
time of 7 h) to assess the presence and severity of OSA. Increas-
ing severity of untreated OSA was associated with poorer glucose
control after controlling for age, sex, race, BMI, number of dia-
betes medications, level of exercise, years of diabetes, and total
sleep time. Compared to patients without OSA (adjusted mean
A1c: 5.7%), the adjusted mean A1c was 7.3% in mild OSA, 7.7%
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in moderate OSA, and 9.7% in severe OSA. Importantly, the
magnitude of these associations is comparable, if not exceed-
ing to those of widely used hypoglycemic medications. Of note,
when only the first 4 h of recording was analyzed, the robust
relationship between OSA severity and A1c was no longer appar-
ent, perhaps due to insufficient recording time for REM sleep
to occur. This would suggest that sleep recordings longer than
the commonly used minimum of 4 h might be needed for bet-
ter assessment of the links between OSA and type 2 diabetes.
Another cross-sectional study (Pillai et al., 2011) involving 52 con-
secutive patients recruited from a diabetes-obesity clinic found
that after adjusting for age, gender, BMI, duration of diabetes,
and insulin dose, increased severity of OSA was associated with
increased A1c levels. The adjusted mean values of A1c in each
OSA category were 8.62% for no OSA, 9.36% for mild, 10.61% for
moderate, and 9.91% for severe OSA. In a smaller study (Fendri
et al., 2011) of 26 overweight and obese individuals with type
2 diabetes, nocturnal glycemia (as assessed by a continuous glu-
cose monitoring sensor) was found to be 38% higher in those
who had OSA, compared to those without OSA, independent
of BMI.
Overall, there is evidence to suggest that the presence and sever-
ity of untreated OSA may be associated with poor glucose control
in type 2 diabetic patients. These findings may have important
clinical implications in the management and care of type 2 dia-
betes as they support the hypothesis that reducing the severity of
OSA may be an adjunct therapeutic strategy to optimize glucose
control.
IS THE PRESENCE AND SEVERITY OF OSA ASSOCIATED
WITH PREDIABETIC STATES SUCH AS INSULIN RESISTANCE
AND GLUCOSE INTOLERANCE?
Over the past few decades, an increasing number of studies from
population and clinic-based cohorts have consistently found a
robust independent association between the presence and sever-
ity of OSA and prediabetic states such as insulin resistance and
glucose intolerance. A comprehensive review of all these studies is
beyond the scope of this article, but has been the topic of several
review articles (Punjabi and Polotsky, 2005; Tasali and Ip, 2008;
Jun and Polotsky, 2009; Levy et al., 2009; Punjabi, 2009; Pamidi
et al., 2010). In the majority of these studies the estimation of
insulin sensitivity was based on the homeostatic model assessment
(HOMA) index, which is a normalized product of fasting glucose
and insulin levels. Several studies have also used the OGTT to
assess glucose and insulin response after glucose ingestion. Inter-
estingly, many of these studies were conducted in men, so the data
on possible gender effects in the associations between OSA, insulin
resistance, and glucose intolerance is lacking. In the majority of
studies, commonly used indices of OSA severity were the apnea-
hypopnea index (AHI) and the frequency as well as the degree of
intermittent hypoxia.
Overall, the prevalence of prediabetes (i.e., the presence of
either IFG and/or IGT) was found to be significantly higher in
patients with OSA than those without OSA, but the estimates have
been variable, ranging between 20 and 67% (Meslier et al., 2003;
Kono et al., 2007; Seicean et al., 2008; Tamura et al., 2008; Fred-
heim et al., 2011). In a large cross-sectional analysis of a subset
of data from the Sleep Heart Health Study, involving over 2500
non-diabetic individuals (Seicean et al., 2008), the presence of
OSA was associated with a significantly higher odds of IFG and
IGT after controlling for age, sex, race, BMI, and waist circum-
ference. Importantly, the magnitude of these associations was
similar in non-overweight and overweight individuals (Seicean
et al., 2008).
In the earliest studies from large population-based samples,
OSA was found to be independently associated with insulin resis-
tance (Ip et al., 2002; Punjabi et al., 2002) and glucose intolerance
(Punjabi et al., 2002). In a clinic-based sample of 595 men, the
increasing severity of OSA was associated with worsening glu-
cose tolerance and insulin resistance, independent of age and BMI
(Meslier et al., 2003). In an earlier report from the Sleep Heart
Health Study, the increasing severity of OSA was independently
associated with both fasting and 2 h post-load glucose levels dur-
ing an OGTT (Punjabi et al., 2004). In a population-based sample
of 400 women, those with severe OSA had significantly lower
insulin sensitivity as compared to those without OSA, and the
severity of OSA was associated with increasing fasting and 2-h
post-challenge insulin levels during an OGTT, after adjusting for
age, waist-hip ratio, and other potential confounders (Theorell-
Haglow et al., 2006). In an analysis of a subset of participants
in the Wisconsin Sleep Cohort Study (n= 546), OSA was sig-
nificantly associated with insulin resistance as measured by the
HOMA index (Nieto et al., 2009). More recently, Punjabi and
Beamer (2009) estimated insulin sensitivity in 118 non-diabetic
adults using a frequently sampled intravenous glucose tolerance
test (ivGTT). The authors found that compared to normal indi-
viduals, those with mild, moderate, and severe OSA showed a 26.7,
36.5, and 43.7% decrease in insulin sensitivity, respectively, after
controlling for age, gender, race, and percent body fat. Despite
this progressive decline in insulin sensitivity, the acute insulin
response to glucose was unchanged, suggesting an insufficient
up-regulation of insulin secretion and thus impaired beta-cell
function. A recent cross-sectional study of 1,599 non-diabetic
patients, where participants with an A1c of ≥6.5%, self-reported
diabetes or use of diabetic medication were excluded, a dose–
response relationship between OSA severity and the percentage
of patients with A1c >6% was observed, suggesting a grad-
ual increase in prediabetic state with increasing severity of OSA
(Priou et al., 2012). Although some of these studies have con-
trolled for adiposity using several surrogate markers (e.g., waist
circumference, percent body fat), central adiposity, particularly
visceral fat is an important confounding factor in the observed
links between OSA and prediabetic states. In this regard, there
is some evidence to suggest that in the absence of confound-
ing effects of visceral adiposity, OSA may still be associated with
insulin resistance and higher fasting glucose levels (Kono et al.,
2007).
A recent study by Pamidi et al. (2012), the researchers assessed
whether the presence of OSA affects glucose metabolism in young,
lean individuals who are healthy and free of cardiometabolic
disease. In a prospective design, 52 healthy men (age range 18–
30 years and BMI range 18–25 kg/m2) underwent a laboratory
polysomnogram followed by a morning OGTT to assess glu-
cose metabolism. All subjects were stratified according to the
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presence or absence of ethnicity-based diabetes risk and family
history of diabetes. The authors then used a frequency match-
ing approach and randomly selected individuals without OSA,
yielding a total of 20 control men without OSA and 12 men
with OSA. Men with OSA and controls were similar in terms
of age, BMI, ethnicity-based diabetes risk, family history of dia-
betes, and level of exercise. Both groups had normal systolic
and diastolic blood pressure and fasting lipid levels. Following
ingestion of a 75-g glucose load, men with OSA had 27% lower
insulin sensitivity (estimated by the Matsuda index during the
OGTT) and 37% higher total insulin secretion than the con-
trols, despite comparable glucose levels. This study is the first
to demonstrate that in young lean men (mean age <24 years,
mean BMI <23 kg/m2) who are otherwise healthy and free of
cardiometabolic disease, the presence of OSA is associated with
insulin resistance and compensatory hyperinsulinemia to main-
tain normal glucose homeostasis. These findings provide evidence
to support the hypothesis that OSA may be associated with early
changes in the natural history of type 2 diabetes even in the absence
of obesity, cardiovascular disease, and other known risk factors for
type 2 diabetes.
In summary, these observational studies strongly support
an association between OSA and insulin resistance and glu-
cose intolerance, even after statistical adjustments for shared
risk factors. However, central adiposity, particularly visceral
fat, needs to be considered as an important confounder
when interpreting these studies. Finally, studies with longitu-
dinal and interventional designs are needed to better address
the potential role of OSA in the development of prediabetic
states.
IS CPAP TREATMENT OF OSA EFFECTIVE IN IMPROVING
GLUCOSE METABOLISM?
EVIDENCE FROM UNCONTROLLED STUDIES
In patients with type 2 diabetes, five uncontrolled studies including
a total of 87 patients examined the effects of continuous posi-
tive airway pressure (CPAP) on glycemic control (Brooks et al.,
1994; Harsch et al., 2004; Babu et al., 2005; Dawson et al., 2008;
Pallayova et al., 2008). Two studies reported improvements in
nighttime glucose levels after one night (Pallayova et al., 2008)
and 5 weeks (Dawson et al., 2008) of CPAP use. Two other stud-
ies showed improvements in insulin sensitivity (as assessed by
the gold standard hyperinsulinemic euglycemic clamp), with-
out a change in A1c levels after 3–4 months of CPAP (Brooks
et al., 1994; Harsch et al., 2004). In contrast, Babu et al. (2005)
found an improvement in A1c and post-prandial glucose levels
after 3 months of CPAP therapy in 25 obese patients with type
2 diabetes. Notably, in patients who used CPAP for more than
4 h/night (averaging ∼6.6 h/night) the decrease in A1c levels was
strongly correlated with the amount of CPAP use (Babu et al.,
2005). One observational cohort study examined the effect of
CPAP on incident diabetes and found that among patients with
moderate to severe OSA, the regular use of CPAP (determined by
physician follow-up) was associated with a significant reduction
of incident diabetes, even after adjusting for subsequent weight
loss during an average of 2.7-year follow-up period (Botros et al.,
2009).
In non-diabetic patients with OSA, numerous uncontrolled
studies have examined the effects of CPAP treatment on predia-
betic states such as glucose tolerance and insulin sensitivity. While
some studies have reported positive findings (Harsch et al., 2004;
Lindberg et al., 2006; Barcelo et al., 2008; Dorkova et al., 2008;
Schahin et al., 2008; Cuhadaroglu et al., 2009; Henley et al., 2009;
Oktay et al., 2009; Steiropoulos et al., 2009b; Mota et al., 2011;
Tasali et al., 2011; Shpirer et al., 2012), others were negative (Saini
et al., 1993; Cooper et al., 1995; Stoohs et al., 1996; Saarelainen
et al., 1997; Ip et al., 2000; Smurra et al., 2001; Czupryniak et al.,
2005; Trenell et al., 2007; Vgontzas et al., 2008; Carneiro et al.,
2009; Comondore et al., 2009; Murri et al., 2009; Garcia et al.,
2011). The majority of studies used the HOMA index (relying on
fasting insulin and glucose levels) as a measure of insulin sensi-
tivity (Czupryniak et al., 2005; Lindberg et al., 2006; Trenell et al.,
2007; Barcelo et al., 2008; Dorkova et al., 2008; Carneiro et al., 2009;
Comondore et al., 2009; Cuhadaroglu et al., 2009; Henley et al.,
2009; Murri et al., 2009; Steiropoulos et al., 2009b; Tasali et al.,
2011), while only a few studies used the gold standard hyper-
insulinemic euglycemic clamp method (Saarelainen et al., 1997;
Smurra et al., 2001; Harsch et al., 2004; Schahin et al., 2008) and
one study used the ivGTT (Tasali et al., 2011). Three studies have
used the standard OGTT method to assess post-challenge glucose
tolerance (Smurra et al., 2001; Henley et al., 2009; Shpirer et al.,
2012). The average CPAP treatment period ranged between one
night and 6 months, with one study reporting findings after almost
3 years of follow-up (Schahin et al., 2008). Notably, only about
half of the studies reported objective data on CPAP use and the
overall reported average CPAP adherence was about 4–5 h/night.
Most studies were conducted in obese men. In one study, CPAP
improved insulin sensitivity (assessed by hyperinsulinemic eug-
lycemic clamp) in 40 men even after 2 days of therapy (Harsch
et al., 2004) and the improvement persisted at 3-months, particu-
larly in those with a BMI less than 30 kg/m2. In contrast, an earlier
study (Smurra et al., 2001) using the hyperinsulinemic euglycemic
clamp and OGTT in 16 obese men found no change in insulin sen-
sitivity or glucose tolerance after 2 months of CPAP. A few studies
reported a positive effect of CPAP on insulin sensitivity in sub-
groups of patients, specifically those who used CPAP for more than
4 h/night (Dorkova et al., 2008; Steiropoulos et al., 2009a) or those
with excessive daytime sleepiness (Barcelo et al., 2008). In one
study,8 weeks of CPAP treatment (average CPAP use∼6.6 h/night)
modestly improved insulin sensitivity (as assessed by ivGTT) in
young women with polycystic ovarian syndrome despite morbid
obesity (Tasali et al., 2011). Importantly, the change in insulin sen-
sitivity correlated positively with CPAP use and negatively with
BMI. In addition, both daytime and nighttime norepinephrine
levels were decreased after CPAP and the reductions were greater
with increased CPAP use, suggesting that the metabolic effects of
CPAP therapy may be modulated by the hours of CPAP use and
the degree of obesity (Tasali et al., 2011).
Overall, the uncontrolled studies that examined the effect of
CPAP therapy on glucose metabolism have yielded mixed results.
This could be partly explained by differences in patient popula-
tion and techniques used to assess glucose metabolism as well as
small sample size, poor adherence to CPAP, and potential changes
in body composition during the studies.
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EVIDENCE FROM RANDOMIZED-CONTROLLED TRIALS
To date, a total of nine studies using randomized-controlled
designs have investigated the effects of CPAP therapy on mea-
sures of glucose metabolism (Table 4). All studies included sham-
CPAP as the control group and most studies were conducted in
men. The duration of intervention period varied between 1 week
and 3 months. Some studies used a parallel group design (West
et al., 2007; Lam et al., 2010; Nguyen et al., 2010; Kohler et al.,
2011; Hoyos et al., 2012) in which patients were randomized to
either CPAP or sham-CPAP, while others used a cross-over design
(Coughlin et al., 2007; Sharma et al., 2011; Sivam et al., 2012; Wein-
stock et al., 2012) where patients were first randomized to CPAP
or sham-CPAP, followed by the alternate therapy after a washout
period. In six of the nine studies (Coughlin et al., 2007; West et al.,
2007; Lam et al., 2010; Sharma et al., 2011; Hoyos et al., 2012; Wein-
stock et al., 2012), measures of glucose metabolism were used as
primary outcome, whereas in the remaining three studies, fasting
glucose (Nguyen et al., 2010; Sivam et al., 2012) and HOMA index
(Kohler et al., 2011) were included as secondary outcomes. Over-
all, only three of the nine studies (Lam et al., 2010; Sharma et al.,
2011; Weinstock et al., 2012) reported positive findings during
the randomized treatment period. One study (Hoyos et al., 2012)
had positive findings only in the open, non-randomized extended
portion of CPAP therapy. Nightly treatment use (CPAP or sham-
CPAP) was 5 h or less in most studies (Coughlin et al., 2007; West
et al., 2007; Nguyen et al., 2010; Sharma et al., 2011; Hoyos et al.,
2012; Sivam et al., 2012; Weinstock et al., 2012) except about 6 h
in one study (Kohler et al., 2011), which a priori included patients
who had been treated with CPAP for more than 12 months with an
average compliance of 4 h/night. In another study with only 1 week
of intervention, CPAP use, but not sham-CPAP, averaged about
6 h (Lam et al., 2010). Sample characteristics, OSA definition,
measures of glucose metabolism, randomized treatment duration,
nightly treatment hours, and main findings on glucose metabo-
lism and other key outcomes from the nine randomized-controlled
trials are summarized in Table 4.
West et al. (2007) studied 42 obese patients with type 2 dia-
betes in a double-blind parallel-design and found no effect of
CPAP on A1c levels or insulin sensitivity (estimated by the eug-
lycemic clamp method), but reported significant improvements in
daytime sleepiness (assessed by the Epworth Sleepiness Scale and
the Maintenance Wakefulness Test) after 3 months of CPAP. Body
composition including BMI, percent body fat (by bioimpedance
technique), waist-hip ratio, and neck size did not change with
treatment. In this study, the average nightly CPAP use was only
about 3.3 h and no correlation was reported between CPAP com-
pliance and measures of insulin resistance and A1c (West et al.,
2007).
Coughlin et al. (2007) investigated the effect of 6 weeks of CPAP
versus sham-CPAP in a cross-over design on cardiovascular and
metabolic outcomes in 34 obese (mean BMI= 36.1 kg/m2) and
non-diabetic men with symptomatic OSA. The authors found
no significant difference in insulin sensitivity (as assessed by the
HOMA index) or the presence of metabolic syndrome after CPAP
use. Similar to the study by West et al. (2007), the average CPAP
use was low, averaging about 3.9 h/night. Despite the relatively
poor CPAP compliance, there was a significant improvement in
blood pressure (Coughlin et al., 2007), suggesting that the amount
and the duration needed to reverse cardiovascular and metabolic
abnormalities may differ.
In a parallel-design study by Lam et al. (2010), 61 non-diabetic
Chinese men with moderate to severe OSA and lesser degree
of obesity (mean BMI= 27.5 kg/m2) were randomized to either
CPAP or sham-CPAP for only 1 week. Those who were in the
CPAP group were also re-assessed at 3 months. Insulin sensitivity
was estimated by the short insulin tolerance test and the HOMA
index. After 1 week of treatment, the CPAP group (about 6.2 h
of average CPAP use) showed reduced insulin resistance and this
improvement in insulin sensitivity was maintained at 3 months in
those who were overweight (BMI of 25 or greater). After 3 months
of CPAP use, there were improvements in blood pressure, plasma
lipids, and urinary catecholamines, but no change was observed in
the amount of visceral fat as measured by MRI (Lam et al., 2010).
In a small study with a parallel design, Nguyen et al. (2010) ran-
domized 20 newly diagnosed, moderate to severe OSA patients to
either CPAP or sham-CPAP for 3 months to investigate the impact
of CPAP therapy on myocardial and endothelial function as main
outcomes. While parameters of cardiovascular function improved
after CPAP, there was no change in fasting glucose levels, which
was included in the study as a secondary outcome.
In the largest trial, Sharma et al. (2011) studied 86 patients
with severe OSA, of which the majority (87%) had metabolic syn-
drome and about 50% were diabetics. The patients were randomly
assigned to 3 months of CPAP followed by 3 months of sham-
CPAP, or vice versa, with a washout period of 1 month in between.
The frequency of the metabolic syndrome was reduced after CPAP
therapy with reversal found in 11 of 86 patients (13%) undergoing
CPAP therapy versus 1 of 86 (1%) undergoing sham-CPAP. A1c
was slightly but significantly improved after CPAP compared to
sham-CPAP, but no significant differences were observed in fast-
ing glucose and insulin levels or insulin resistance as assessed by
HOMA index. The authors also observed small, but significant
reductions in blood pressure, lipids, and BMI (−0.3 unit differ-
ence between CPAP versus sham-CPAP groups) as well as reduc-
tions in visceral and subcutaneous fat, quantified by computerized
tomography.
Weinstock et al. (2012) randomized 50 patients (mean
BMI= 39 kg/m2) with prediabetes and moderate to severe OSA
to either 2 months of CPAP or sham-CPAP in a cross-over design
with a 1-month washout period. Prior to randomization, each
patient was enrolled in a 2-week run-in period, and only those
who met minimal adherence criteria during the run-in period
were then randomized. The primary outcome was normalization
of IGT status as assessed by 2 h glucose levels during an OGTT.
Although the study did not show that IGT normalizes after CPAP
(average use was 4.8 h in the CPAP group), there was improvement
in insulin sensitivity (assessed by the Gutt index) and 2 h insulin
levels in a subgroup of patients with severe OSA who had an AHI
of 30 or greater. Notably, for each hour of CPAP use, the mean
change in insulin sensitivity from baseline increased by 4.2%.
Interestingly, sleepy patients with an Epworth Sleepiness score of
16 or greater had larger improvements in insulin sensitivity, fasting
insulin, and 2-h insulin as compared to non-sleepy subjects. This
study also controlled for individual differences in sleep duration
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and visceral fat (as assessed by computerized tomography) in the
analyses.
In the study by Kohler et al. (2011) 41 patients with OSA who
were treated with CPAP were randomized to either CPAP with-
drawal (sub-therapeutic CPAP), or continued CPAP, for 2 weeks.
CPAP withdrawal resulted in rapid recurrence of OSA, increased
subjective sleepiness, impaired endothelial function, increased uri-
nary catecholamines, and elevated blood pressure and heart rate.
However, there was no change in lipids or insulin sensitivity as
estimated by the HOMA index.
Sivam et al. (2012) studied 27 patients who received both ther-
apeutic and sham-CPAP in random order for 2 months with an
intervening 1 month washout period. No difference was found in
subcutaneous, visceral, and liver fat (primary outcomes) or fasting
glucose levels (secondary outcome) between treatment arms.
The study by Hoyos et al. (2012) included 65 non-diabetic,
obese men (mean BMI= 31.3 kg/m2) with moderate to severe
OSA who were randomized to therapeutic or sham-CPAP for
3 months in a parallel group design. At the end of 3 months, all
patients received therapeutic CPAP for an additional 3 months.
The primary outcomes (from baseline to 12 weeks) were the
change in visceral fat by computerized tomography and the change
in insulin sensitivity based on OGTT. Although there were no
differences in insulin sensitivity between the two groups after
12 weeks, the entire group using CPAP showed improved insulin
sensitivity as compared to baseline at the end of 24 weeks during
the non-randomized portion of the study (Hoyos et al., 2012).
Of note, the therapeutic CPAP pressure was determined by an at-
home titration, which may not be optimal, and the average CPAP
use was only 3.6 h. Even though subgroup analyses were performed
in “more compliant” patients (average use>4 h/night), there were
only 5 out of 65 (8%) patients who used CPAP for more than 6 h.
In conclusion, there is still controversy as to whether CPAP
treatment of OSA improves glucose metabolism. There is some
evidence to support the hypothesis that the degree of obesity and
the amount of CPAP use may be important factors in the metabolic
response to CPAP. The current data also suggest that the effects of
CPAP may vary according to the measured outcome. Large-scale
randomized-controlled trials with robust assessments of insulin
sensitivity and glucose tolerance will be required to fully deter-
mine the metabolic effects of CPAP. Moreover, future studies are
also needed to investigate the optimal duration and the amount of
CPAP use that is required to improve metabolic outcomes. Such
interventional studies would be essential to address whether there
is a causal link between OSA and alterations in glucose metabo-
lism. Future studies should aim to determine subgroups of OSA
patients who possess certain characteristics that make them more
likely to get metabolic benefit from CPAP therapy. Identification of
these metabolic phenotypes of OSA who are responsive to CPAP
therapy could be a key factor in the clinical management and care
of patients with prediabetes and type 2 diabetes.
WHAT ARE THE POTENTIAL MECHANISMS UNDERLYING
THE LINK BETWEEN OSA AND INSULIN RESISTANCE AND
GLUCOSE INTOLERANCE?
The two major characteristics of OSA, namely intermittent
hypoxia and sleep fragmentation can lead to derangements in
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glucose metabolism by several mechanisms including activations
of the sympathetic nervous system and hypothalamic-pituitary
axis, and changes in the inflammatory pathways (Jun and Polot-
sky, 2009). Other putative mechanisms include hypoxic injury
to pancreas and potential alterations in central (e.g., hypothal-
amic) pathways for glucose control. Animal models mimicking
OSA have been used to elucidate the potential mechanisms that
may be responsible for metabolic dysregulation in OSA. Inter-
mittent hypoxia stimuli of varying frequency and severity were
used in rodents when they are most likely to be asleep. In one
study, electroencephalogram tracings were recorded and showed
that intermittent hypoxia stimuli were accompanied by arousals,
suggesting that sleep fragmentation is also an intrinsic feature of
these hypoxia models (Polotsky et al., 2006). In these models, inter-
mittent hypoxia led to sympathetic activation and hypertension
(Fletcher et al., 1992; Fletcher, 2003), insulin resistance in both
lean (Iiyori et al., 2007) and obese (Polotsky et al., 2003) rodents,
impaired glucose homeostasis (Yokoe et al., 2008), and pancre-
atic beta-cell proliferation (Yokoe et al., 2008; Xu et al., 2009)
as well as apoptosis of beta-cells (Yokoe et al., 2008; Xu et al.,
2009). In a study by Gharib et al. (2012) mice that were exposed
to 6 h of sleep fragmentation by the movement of an automated
bar showed insulin resistance and glucose intolerance as well as
altered transcriptional profile of visceral adipocytes. In healthy
humans, one study that used intermittent hypoxia selectively
during sleep found that 2–4 weeks of exposure to intermittent
hypoxia resulted in increased morning blood pressure (Tamisier
et al., 2009), but glucose metabolism was not assessed. Another
study exposed healthy subjects to 5 h of intermittent hypoxia or
normoxia during wakefulness and reported a decreased insulin
sensitivity estimated by ivGTT (Louis and Punjabi, 2009). Two
studies exposed healthy subjects to sleep fragmentation using
acoustic stimuli and examined the effects on glucose metabolism
by ivGTT. In the first study by Tasali et al. (2008a), all night selec-
tive suppression of slow wave sleep for three consecutive nights
resulted in an approximate 25% decrease in insulin sensitivity
without adequate compensatory rise in insulin secretion, lead-
ing to reduced glucose tolerance and increased diabetes risk (i.e.,
decreased disposition index). In the second study, non-selective
sleep fragmentation for two nights was associated with a decrease
in insulin sensitivity and non-insulin dependent glucose disposal
(Stamatakis and Punjabi, 2009). In contrast to the study by Tasali et
al. the second study noted an increase in the acute insulin response
to glucose, suggesting that the beta-cell function was preserved.
Notably, the second study was also associated with marked reduc-
tions in slow wave sleep, whereas other sleep stages were only
minimally affected. Both of these sleep fragmentation studies were
associated with elevated cardiac sympathetic output (Tasali et al.,
2008a; Stamatakis and Punjabi, 2009). Overall, data from animal
and human models that mimic OSA support an adverse effect
of OSA on insulin resistance, glucose intolerance, and increased
diabetes risk. The relative contributions of intermittent hypoxia
versus sleep fragmentation on cardiometabolic outcomes remain
to be determined.
In summary, current evidence strongly supports an indepen-
dent association between OSA and insulin resistance and glucose
intolerance, but a causal link remains to be determined. A sub-
stantial proportion of patients with type 2 diabetes suffer from
unrecognized OSA. Conversely, type 2 diabetes is more preva-
lent among patients with OSA compared to those without OSA.
Thus, the role of OSA in the management of type 2 diabetes is
in urgent need of further rigorous assessment. The question of
whether OSA represents an independent risk for the develop-
ment of prediabetes and type 2 diabetes over time remains to be
investigated by large prospective studies. Notably, weight loss, if
successfully achieved can improve both OSA and glucose control,
and thus should be recommended systematically to all patients
with OSA. There is still debate whether CPAP treatment of OSA
improves glucose metabolism. Also, the sufficient amount and
duration of CPAP that is required to improve metabolic outcomes
remains to be determined. Large-scale randomized-controlled tri-
als of CPAP treatment of OSA with well-validated assessments of
insulin sensitivity and glucose tolerance are needed. Identifica-
tion of phenotypes of OSA patients who show better metabolic
response to CPAP therapy would be important.
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